Phathom Pharmaceuticals (PHAT) Short Interest Ratio & Short Volume $3.36 -0.94 (-21.79%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Phathom Pharmaceuticals Short Interest DataPhathom Pharmaceuticals (PHAT) has a short interest of 11.38 million shares, representing 21.93% of the float (the number of shares available for trading by the public). This marks a -11.85% decrease in short interest from the previous month. The short interest ratio (days to cover) is 9.5, indicating that it would take 9.5 days of the average trading volume of 1.05 million shares to cover all short positions.Current Short Interest11,380,000 sharesPrevious Short Interest12,910,000 sharesChange Vs. Previous Month-11.85%Dollar Volume Sold Short$54.28 millionShort Interest Ratio9.5 Days to CoverLast Record DateApril 15, 2025Outstanding Shares69,648,000 sharesShort Percent of Float21.93%Today's Trading Volume4,435,920 sharesAverage Trading Volume1,046,112 sharesToday's Volume Vs. Average424% Short Selling Phathom Pharmaceuticals? Sign up to receive the latest short interest report for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPHAT Short Interest Over TimePHAT Days to Cover Over TimePHAT Percentage of Float Shorted Over Time Phathom Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202511,380,000 shares $54.28 million -11.9%21.9%9.5 $4.77 3/31/202512,910,000 shares $80.95 million -10.1%24.9%10.9 $6.27 3/15/202514,360,000 shares $63.33 million +3.2%27.7%12.7 $4.41 2/28/202513,920,000 shares $76.84 million -6.3%26.8%13.3 $5.52 2/15/202514,860,000 shares $85.74 million +1.6%28.6%14.7 $5.77 1/31/202514,630,000 shares $87.63 million +3.0%N/A11.3 $5.99 1/15/202514,200,000 shares $101.25 million -5.0%N/A11.1 $7.13 12/31/202414,950,000 shares $121.39 million +5.8%N/A11.8 $8.12 12/15/202414,130,000 shares $111.49 million +0.6%N/A11 $7.89 11/30/202414,050,000 shares $124.62 million -4.2%N/A10.7 $8.87 Get the Latest News and Ratings for PHAT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/202414,660,000 shares $128.71 million -16.0%N/A10.9 $8.78 10/31/202417,450,000 shares $299.27 million -0.6%N/A16.3 $17.15 10/15/202417,560,000 shares $274.99 million +2.0%N/A18.5 $15.66 9/30/202417,220,000 shares $311.34 million +11.0%N/A18 $18.08 9/15/202415,520,000 shares $284.02 million +1.2%N/A17.4 $18.30 8/31/202415,340,000 shares $253.42 million +7.7%N/A19.8 $16.52 8/15/202414,250,000 shares $186.75 million +3.8%N/A20.4 $13.11 7/31/202413,730,000 shares $162.29 million +5.0%49.5%21 $11.82 7/15/202413,080,000 shares $165.72 million -2.4%47.1%20.5 $12.67 6/30/202413,400,000 shares $138.02 million +2.3%47.9%22.9 $10.30 6/15/202413,100,000 shares $148.69 million +6.2%46.8%20.7 $11.35 5/31/202412,330,000 shares $116.15 million +1.2%44.1%18.8 $9.42 5/15/202412,180,000 shares $126.79 million +3.2%43.2%16.3 $10.41 4/30/202411,800,000 shares $106.55 million -1.9%41.9%13.4 $9.03 4/15/202412,030,000 shares $120.54 million +13.0%43.5%13.7 $10.02 3/31/202410,650,000 shares $113.10 million +2.0%40.0%12 $10.62 3/15/202410,440,000 shares $88.64 million +20.4%40.1%13 $8.49 2/29/20248,670,000 shares $92.77 million -6.3%34.0%11.4 $10.70 2/15/20249,250,000 shares $63.83 million +7.2%36.3%13.2 $6.90 1/31/20248,630,000 shares $57.82 million +5.4%32.4%14.9 $6.70 1/15/20248,190,000 shares $61.92 million +15.7%30.8%14.3 $7.56 12/31/20237,080,000 shares $64.64 million +12.9%26.6%13.9 $9.13 12/15/20236,270,000 shares $54.67 million +14.0%23.6%12.9 $8.72 11/30/20235,500,000 shares $38.45 million +12.9%20.9%10.5 $6.99 11/15/20234,870,000 shares $35.75 million +18.2%18.5%10.4 $7.34 10/31/20234,120,000 shares $38.32 million +4.3%16.1%9.6 $9.30 10/15/20233,950,000 shares $39.86 million +0.8%15.4%10.9 $10.09 9/30/20233,920,000 shares $40.65 million +42.0%15.3%11.2 $10.37 9/15/20232,760,000 shares $36.16 million -0.4%10.8%8 $13.10 8/31/20232,770,000 shares $39.86 million +7.0%11.0%9.3 $14.39Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 8/15/20232,590,000 shares $39.98 million -18.8%10.3%7.4 $15.44 7/31/20233,190,000 shares $48.52 million -25.8%12.2%9.4 $15.21 7/15/20234,300,000 shares $60.46 million +1.7%15.9%12.9 $14.06 6/30/20234,230,000 shares $60.57 million -3.0%14.8%11.4 $14.32 6/15/20234,360,000 shares $55.02 million +4.8%15.2%10.6 $12.62 5/31/20234,160,000 shares $48.92 million -8.0%20.2%10 $11.76 5/15/20234,520,000 shares $56.91 million -7.2%24.7%10.9 $12.59 4/30/20234,870,000 shares $52.11 million +0.4%33.1%11.7 $10.70 4/15/20234,850,000 shares $48.40 million +33.6%27.5%11.5 $9.98 3/31/20233,630,000 shares $25.92 million +18.6%20.8%8.4 $7.14 3/15/20233,060,000 shares $21.42 million +2.7%17.5%7.7 $7.00 2/28/20232,980,000 shares $25.51 million +10.8%15.8%8.4 $8.56 2/15/20232,690,000 shares $25.04 million +18.5%14.3%7.8 $9.31 1/31/20232,270,000 shares $27.08 million +8.6%12.1%8.9 $11.93 1/15/20232,090,000 shares $17.28 million +10.6%11.0%9.1 $8.27 12/30/20221,890,000 shares $21.21 million +18.9%10.0%9.2 $11.22 12/15/20221,590,000 shares $16.15 million -0.6%8.4%11.7 $10.16 11/30/20221,600,000 shares $15.97 million -5.3%8.4%7.7 $9.98 11/15/20221,690,000 shares $17.46 million -8.2%8.9%8 $10.33 10/31/20221,840,000 shares $19.50 million -8.5%11.1%8.1 $10.60 10/15/20222,010,000 shares $19.58 million -54.5%12.1%6.9 $9.74 9/30/20224,420,000 shares $48.97 million -22.5%26.7%15.6 $11.08 9/15/20225,700,000 shares $56.83 million -1.0%29.7%19.3 $9.97 8/31/20225,760,000 shares $49.19 million +4.9%30.1%23 $8.54 8/15/20225,490,000 shares $63.41 million +73.2%28.7%20.6 $11.55 7/31/20223,170,000 shares $29.20 million -1.9%16.6%9.7 $9.21 7/15/20223,230,000 shares $31.10 million +0.3%16.6%11.9 $9.63 6/30/20223,220,000 shares $27.18 million -0.6%16.5%11.7 $8.44 6/15/20223,240,000 shares $21.22 million +2.5%16.6%12 $6.55 5/31/20223,160,000 shares $22.66 million +1.9%16.2%13.3 $7.17 5/15/20223,100,000 shares $24.77 million +24.0%15.9%14.7 $7.99 4/30/20222,500,000 shares $32.35 million +2.5%12.5%17.3 $12.94 4/15/20222,440,000 shares $35.97 million +17.9%19.3%19.7 $14.74 3/31/20222,070,000 shares $28.17 million +15.6%16.4%16.1 $13.61 3/15/20221,790,000 shares $20.67 million -50.6%14.2%14.3 $11.55 2/28/20223,620,000 shares $65.63 million +3.7%18.4%29.8 $18.13 2/15/20223,490,000 shares $68.75 million +2.1%17.7%26.6 $19.70 1/31/20223,420,000 shares $57.46 million -2.6%19.0%24.3 $16.80 1/15/20223,510,000 shares $53.21 million -20.4%19.5%22.7 $15.16 12/31/20214,410,000 shares $86.74 million +43.7%24.4%24 $19.67 12/15/20213,070,000 shares $58.70 million +2.7%17.0%17 $19.12 11/30/20212,990,000 shares $53.64 million -21.1%16.6%17.1 $17.94 11/15/20213,790,000 shares $81.75 million +6.8%21.0%23.1 $21.57 10/29/20213,550,000 shares $83.53 million +100.6%20.6%23.8 $23.53 10/15/20211,770,000 shares $57.54 million +17.2%10.3%15 $32.51 9/30/20211,510,000 shares $48.47 million +7.9%8.8%18.9 $32.10 9/15/20211,400,000 shares $46.44 million -12.5%8.1%14.4 $33.17 8/31/20211,600,000 shares $56.94 million +1.3%9.3%17.3 $35.59 8/13/20211,580,000 shares $50.56 million +21.5%9.2%16.5 $32.00 7/30/20211,300,000 shares $41.73 million +4.8%7.5%12.9 $32.10Musk's warning signal: Prepare before the cascade begins (Ad)When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t. With 40+ years of market modeling, he says Musk’s move wasn’t about efficiency — it was a signal. And what’s coming next could divide the market into winners and losers faster than anyone expects. Watch this urgent video briefing now.Watch the Musk market warning before the dominoes fall 7/15/20211,240,000 shares $42.45 million +0.8%7.2%11.9 $34.23 6/30/20211,230,000 shares $41.64 million +19.4%7.1%12 $33.85 6/15/20211,030,000 shares $34.43 million +3.1%6.0%11.2 $33.43 5/28/2021999,400 shares $35.33 million +2.6%5.8%10.1 $35.35 5/14/2021973,700 shares $33.10 million +39.6%6.0%9.9 $33.99 4/30/2021697,700 shares $27.78 million +15.4%4.3%7.1 $39.81 4/15/2021604,800 shares $23.19 million +6.5%3.8%6.3 $38.35 3/31/2021568,000 shares $20.62 million +3.7%3.5%5.7 $36.31 3/15/2021547,600 shares $24.75 million +31.4%3.4%4.4 $45.19 2/26/2021416,800 shares $19.19 million -11.8%2.6%2.9 $46.04 2/12/2021472,600 shares $21.03 million -1.9%3.0%3.4 $44.49 1/29/2021481,600 shares $18.84 million -15.8%3.0%3.6 $39.11 1/15/2021571,900 shares $21.88 million -29.3%3.6%4.4 $38.25 12/31/2020809,400 shares $27.26 million +21.6%5.5%6.9 $33.68 12/15/2020665,700 shares $29.60 million -12.6%4.6%6.5 $44.46 11/30/2020761,400 shares $32.84 million -5.0%5.6%13.9 $43.13 11/15/2020801,400 shares $32.50 million -4.1%6.0%16.4 $40.55 10/30/2020835,500 shares $33.08 million +0.6%6.3%17.6 $39.59 10/15/2020830,900 shares $32.45 million +1.6%6.3%18.1 $39.05 9/30/2020817,800 shares $29.99 million -2.0%6.2%16.2 $36.67 9/15/2020834,300 shares $29.62 million -4.3%6.3%14.7 $35.50 8/31/2020871,900 shares $32.05 million -5.3%6.6%11.5 $36.76 8/14/2020921,000 shares $36.52 million -13.1%7.0%10.7 $39.65 7/31/20201,060,000 shares $35.26 million -11.7%8.0%12.1 $33.26 7/15/20201,200,000 shares $36.07 million -4.0%9.1%13.9 $30.06 6/30/20201,250,000 shares $42.03 million +22.6%9.4%14.9 $33.62 6/15/20201,020,000 shares $44.00 million No Change7.7%12.7 $43.14 5/29/20201,020,000 shares $43.13 million +2.0%8.6%14.7 $42.28 5/15/20201,000,000 shares $38.55 million +1.5%8.4%15.4 $38.55 PHAT Short Interest - Frequently Asked Questions What is Phathom Pharmaceuticals' current short interest? Short interest is the volume of Phathom Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 11,380,000 shares of PHAT short. 21.93% of Phathom Pharmaceuticals' shares are currently sold short. Learn More on Phathom Pharmaceuticals' current short interest. What is a good short interest ratio for Phathom Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PHAT shares currently have a short interest ratio of 10.0. Learn More on Phathom Pharmaceuticals's short interest ratio. Which institutional investors are shorting Phathom Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Phathom Pharmaceuticals: Group One Trading LLC, Citadel Advisors LLC, Jane Street Group LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Phathom Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 21.93% of Phathom Pharmaceuticals' floating shares are currently sold short. Is Phathom Pharmaceuticals' short interest increasing or decreasing? Phathom Pharmaceuticals saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 11,380,000 shares, a decline of 11.9% from the previous total of 12,910,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Phathom Pharmaceuticals' short interest compare to its competitors? 21.93% of Phathom Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Phathom Pharmaceuticals: Dyne Therapeutics, Inc. (18.94%), Aurinia Pharmaceuticals Inc. (9.00%), Syndax Pharmaceuticals, Inc. (25.86%), Adaptive Biotechnologies Co. (7.14%), Iovance Biotherapeutics, Inc. (26.88%), Wave Life Sciences Ltd. (10.79%), 89bio, Inc. (16.51%), Collegium Pharmaceutical, Inc. (14.46%), Mineralys Therapeutics, Inc. (15.91%), Intellia Therapeutics, Inc. (28.92%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Phathom Pharmaceuticals stock? Short selling PHAT is an investing strategy that aims to generate trading profit from Phathom Pharmaceuticals as its price is falling. PHAT shares are trading down $0.94 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Phathom Pharmaceuticals? A short squeeze for Phathom Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PHAT, which in turn drives the price of the stock up even further. How often is Phathom Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PHAT, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies DYN Short Squeeze AUPH Short Squeeze SNDX Short Squeeze ADPT Short Squeeze IOVA Short Squeeze WVE Short Squeeze ETNB Short Squeeze COLL Short Squeeze MLYS Short Squeeze NTLA Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PHAT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHAT Stock Free PHAT Stock Alerts